LEFTY2/endometrial bleeding-associated factor up-regulates Na+ Coupled Glucose Transporter SGLT1 expression and Glycogen Accumulation in Endometrial Cancer Cells.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
08
02
2019
accepted:
20
02
2020
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
14
7
2020
Statut:
epublish
Résumé
LEFTY2 (endometrial bleeding associated factor; EBAF or LEFTYA), a cytokine released shortly before menstrual bleeding, is a negative regulator of cell proliferation and tumour growth. LEFTY2 down-regulates Na+/H+ exchanger activity with subsequent inhibition of glycolytic flux and lactate production in endometrial cancer cells. Glucose can be utilized not only for glycolysis but also for glycogen formation. Both glycolysis and glycogen formation require cellular glucose uptake which could be accomplished by the Na+ coupled glucose transporter-1 (SGLT1; SLC5A1). The present study therefore explored whether LEFTY2 modifies endometrial SGLT1 expression and activity as well as glycogen formation. Ishikawa and HEC1a cells were exposed to LEFTY2, SGLT1 and glycogen synthase (GYS1) transcript levels determined by qRT-PCR. SGLT1, GYS1 and phospho-GYS1 protein abundance was quantified by western blotting, cellular glucose uptake from 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) uptake, and cellular glycogen content utilizing an enzymatic assay and subsequent colorimetry. As a result, a 48-hour treatment with LEFTY2 significantly increased SGLT1 and GYS1 transcript levels as well as SGLT1 and GYS1 protein abundance in both Ishikawa and HEC1a cells. 2-NBDG uptake and cellular glycogen content were upregulated significantly in Ishikawa (type 1) but not in type 2 endometrial HEC1a cells, although there was a tendency of increased 2-NBDG uptake. Further, none of the effects were seen in human benign endometrial cells (HESCs). Interestingly, in both Ishikawa and HEC1a cells, a co-treatment with TGF-β reduced SGLT1, GYS and phospho-GYS protein levels, and thus reduced glycogen levels and again HEC1a cells had no significant change. In conclusion, LEFTY2 up-regulates expression and activity of the Na+ coupled glucose transporter SGLT1 and glycogen synthase GYS1 in a cell line specific manner. We further show the treatment with LEFTY2 fosters cellular glucose uptake and glycogen formation and TGF-β can negate this effect in endometrial cancer cells.
Identifiants
pubmed: 32236143
doi: 10.1371/journal.pone.0230044
pii: PONE-D-19-03804
pmc: PMC7112196
doi:
Substances chimiques
LEFTY2 protein, human
0
Left-Right Determination Factors
0
SLC5A1 protein, human
0
Sodium-Glucose Transporter 1
0
Glycogen
9005-79-2
Sodium
9NEZ333N27
Glycogen Synthase
EC 2.4.1.11
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0230044Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Dev Biol. 2014 Jul 1;391(1):81-8
pubmed: 24709321
FASEB J. 2004 Aug;18(11):1303-5
pubmed: 15180958
Curr Top Membr. 2012;70:275-311
pubmed: 23177990
Pharmacol Ther. 2009 Jan;121(1):29-40
pubmed: 18992769
Nat Rev Cancer. 2013 Sep;13(9):611-23
pubmed: 23969692
J Neurol Sci. 2014 Dec 15;347(1-2):137-42
pubmed: 25304053
Pharmacol Ther. 2012 Oct;136(1):69-81
pubmed: 22800800
Pharmacol Ther. 2017 Feb;170:148-165
pubmed: 27773781
FASEB J. 2013 Jun;27(6):2165-74
pubmed: 23407711
Front Biosci. 2008 May 01;13:7193-201
pubmed: 18508727
Nat Rev Clin Oncol. 2017 Feb;14(2):85-99
pubmed: 27502359
Endocr Rev. 2014 Dec;35(6):851-905
pubmed: 25141152
Nature. 1990 Nov 22;348(6299):302-8
pubmed: 2123524
Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4329-34
pubmed: 18334633
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Metabolism. 2016 Feb;65(2):124-39
pubmed: 26773935
J Biol Chem. 2010 May 14;285(20):14898-908
pubmed: 20167604
Cell Physiol Biochem. 2017;41(6):2374-2382
pubmed: 28467979
Biochem Cell Biol. 2014 Dec;92(6):449-59
pubmed: 25372771
Mol Cancer Ther. 2017 May;16(5):787-792
pubmed: 28468864
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Res. 2004 Jun 1;64(11):3892-9
pubmed: 15172999
Trends Biochem Sci. 2016 Mar;41(3):211-218
pubmed: 26778478
Philos Trans R Soc Lond B Biol Sci. 1981 Jun 26;293(1063):5-22
pubmed: 6115423
Cancer Invest. 2008 Oct;26(8):852-9
pubmed: 18853313
Exp Biol Med (Maywood). 2002 Oct;227(9):724-52
pubmed: 12324653
Curr Med Chem. 2011;18(36):5519-27
pubmed: 22172062
Oncogene. 2013 Feb 14;32(7):819-26
pubmed: 22469982
Med Oncol. 2011 Dec;28 Suppl 1:S197-203
pubmed: 21080109
Prostate. 2013 Sep;73(13):1453-61
pubmed: 23765757
Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38
pubmed: 23506862
J Reprod Dev. 2014;60(6):438-46
pubmed: 25225159
J Immunol. 2010 Sep 15;185(6):3498-503
pubmed: 20729331
BMJ. 2016 Jul 10;354:i3832
pubmed: 27401748
Physiology (Bethesda). 2017 Nov;32(6):435-443
pubmed: 29021363
Reprod Biol Endocrinol. 2009 Oct 29;7:122
pubmed: 19874624
Sci Rep. 2017 Oct 3;7(1):12612
pubmed: 28974690
J Cell Physiol. 2010 Nov;225(2):390-3
pubmed: 20568225
J Biol Chem. 2016 Nov 4;291(45):23662-23671
pubmed: 27629415
Dev Biol. 2014 Feb 1;386(1):123-34
pubmed: 24333178
Sci Rep. 2014 Feb 06;4:3894
pubmed: 24503642
Dev Biol. 2014 Sep 1;393(1):109-23
pubmed: 24972089
Pancreas. 2012 Jul;41(5):745-52
pubmed: 22441145
Biochem Biophys Res Commun. 2015 May 8;460(3):845-9
pubmed: 25838200
Cell. 1998 Dec 11;95(6):737-40
pubmed: 9865691
Expert Opin Investig Drugs. 2010 Jan;19(1):77-91
pubmed: 20001556
Philos Trans R Soc Lond B Biol Sci. 2014 Feb 03;369(1638):20130100
pubmed: 24493748
Ann N Y Acad Sci. 2011 Mar;1221:98-102
pubmed: 21401636
Pflugers Arch. 2004 Feb;447(5):510-8
pubmed: 12748858
Sci Adv. 2016 May 27;2(5):e1600200
pubmed: 27386546
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4111-9
pubmed: 26170283